The chromosomal translocation t(15;17)(q22;q12) is a consistent feature of acute promyelocytic leukemia (APL) that results in the disruption of genes for the zinc finger transcription factor PML and the retinoic acid receptor ot (RARot). We have previously shown that PML is a growth suppressor and is able to suppress transformation of NIH/3T3 by activated neu oncogene. In the study presented here, the full-length PML cDNA was transfected into B104-1-1 cells (NIH/3T3 cells transformed by the activated neu oncogene) by retrovirally mediated gene transfer. We found that expression of PML could reverse phenotypes of B104-1-1 including morphology, contactlimiting properties, and growth rate in both transient-expression and stable transfectants. We also demonstrated that PML is able to suppress clonogenicity of B104-1-1 in soft agar assay and tumorigenicity in nude mice. These results strongly support our previous finding that PML is a transformation or growth suppressor. Our results further demonstrate that expression of PML in B104-1-1 cells has little effect on cell cycle distribution. Western blot analysis demonstrated that suppression ofneu expression in B104-1-1 by PML was insignificant in the transient transfection experiment but significant in the PML stable transfectants. This study suggests that PML may suppress neu expression and block signaling events associated with activated neu. This study supports our hypothesis that disruption of the normal function of PML, a growth or transformation suppressor, is a critical event in APL leukemogenesis.
Sulnmary
The chromosomal translocation t(15;17)(q22;q12) is a consistent feature of acute promyelocytic leukemia (APL) that results in the disruption of genes for the zinc finger transcription factor PML and the retinoic acid receptor ot (RARot). We have previously shown that PML is a growth suppressor and is able to suppress transformation of NIH/3T3 by activated neu oncogene. In the study presented here, the full-length PML cDNA was transfected into B104-1-1 cells (NIH/3T3 cells transformed by the activated neu oncogene) by retrovirally mediated gene transfer. We found that expression of PML could reverse phenotypes of B104-1-1 including morphology, contactlimiting properties, and growth rate in both transient-expression and stable transfectants. We also demonstrated that PML is able to suppress clonogenicity of B104-1-1 in soft agar assay and tumorigenicity in nude mice. These results strongly support our previous finding that PML is a transformation or growth suppressor. Our results further demonstrate that expression of PML in B104-1-1 cells has little effect on cell cycle distribution. Western blot analysis demonstrated that suppression ofneu expression in B104-1-1 by PML was insignificant in the transient transfection experiment but significant in the PML stable transfectants. This study suggests that PML may suppress neu expression and block signaling events associated with activated neu. This study supports our hypothesis that disruption of the normal function of PML, a growth or transformation suppressor, is a critical event in APL leukemogenesis.
A ute promyelocytic leukemia (APL) 1 represents a clonal expansion of the leukemia blast at the promyelocyte stage of myeloid differentiation. The nonrandom chromosomal translocation t(15;17)(q22;q12) is a consistent cytogenetic hallmark for APL (1, 2) . This translocation event results in the disruption of the PML gene on chromosome 15 and the retinoic acid receptor ol (RARc~) gene on chromosome 17 (3) (4) (5) (6) (7) (8) . In addition, the translocation results in formation of the PML-RAR~ and RARot-PML fusion genes, which are transcriptionally active and encode PML-RAR~ and RARoe-PML fusion proteins (3) (4) (5) (6) (7) (8) . The PML-RARol fusion protein consists of the entire functional domains of the PML and RARoe genes, and it may play an important role in APL leukemogenesis (9) .
The involvement of the RARot gene in the t(15;17) breakpoint of APL has been an interesting subject to many investigators, especially for the remarkable responsiveness of APL to all-trans-retinoic acid therapy (10) (11) (12) . However, disrup-1 Abbreviations used in this paper: APL, acute promyelocytic leukemia; BCS, bovine calf serum; G418 k, G418 resistant; HXM, hypoxanthine, xanthine, and mycophenolic acid; Neo R, neomycin resistance gene; PKC, protein kinase c; PLC, phospholipase C; RA, retinoic acid; RARe, retinoic acid receptor ~x; RXR, retinoid X receptor; TBS, Tris-buffered saline.
tion of the RARc~ gene in APL is insufficient for the development of APL. This is illustrated in HL-60 cells, which lose RA sensitivity because of a mutation that disrupts the normal function of RAR.oe: sensitivity can be restored by increased expression of other forms of RAR or retinoid X receptor (RXR) (13) . It is now clear that expression of the PML-RARo~ protein in myeloid precursor cells can induce RA sensitivity (9) . Furthermore, APL-derived NB4 cells (14) that lose their RA inducibility also lose the expression of PML-RARce protein (15) .
Although RARol biologic function as a R_A-dependent transcription factor has been well characterized, the functional role of PML remains relatively unknown. PML belongs to a novel family of proteins corresponding to a subgroup of a large family that possess a "ring finger" (16) . Nuclear proteins in this family share common structural features: a cysteine/histidine-rich motif at the NH2 terminus followed by a predicted coiled-coil structure (7, 17, 18) . The COOH terminus of the predicted PML protein consists of a proline/ serine-rich region, which suggests that PML may be a phosphoprotein and a substrate for serine/threonine protein kinase and/or phosphatase (6) . This proline/serine-rich region is deleted in the PML/RARo~. Similar events have been seen in other members of that family in the context of oncogenic fusion (7).
The PML-RARot fusion protein is able to form a homodimer through the coiled-coil regions of the PML protein. This homodimer was shown to have distinct DNA binding properties when compared with the RAR/RXR heterodimer (19) . Physiologically, heterodimerization between RAR and RXR is required for efficient binding of the PML-RARot fusion protein to target sequences (7, 19, 20) . In APL, PMLRARot can heterodimerize with PML or RXR. Thus the fusion protein can potentially be a dominant negative inhibitor of PML and RXR (7, 19) . It is noteworthy that sequestration of RXR by heterodimerization with PML-RARol may inhibit the heterodimerization of RXR with some hormone receptors like RARs, thyroid hormone receptor, and vitamin D3 receptor (7, 9, 19) . In turn, the normal biological function of these receptors will be impeded and hamper the ability of the cell to respond to differentiation induction by its ligands (e.g., vitamin D, thyroid hormone) and therefore may result in a differentiation arrest.
A multistep process of oncogenesis is required for most other tumors, but in APL the t(15;17) translocation is usually the only consistent cytogenetic abnormality found (2) , and no other molecular events, for example, mutations in the RAS and p53 genes, have been noted (21) . Consequently, we decided to address whether the loss of PML function in APL, in addition to sequestration of RXR and alteration of RARot, may contribute to leukemogenesis. In our previous study, we showed that PML is a growth suppressor and able to suppress loci formation induced by the activated neu oncogene (22) . Thus, we chose the mutation-activated neutransformed NIH/3T3 line, B104-1-1, as a model to study the effects of PML on oncogenesis. In this study, we found that constitutive expression of PML could reverse the phenotype of B104-1-1 cells, suppress clonogenicity in a soft agar assay, and suppress tumorigenicity in nude mice. The possible mechanism of PML effect on growth and the role of PML in APL pathogenesis were also discussed.
Materials and Methods
Cell Lines. The B104-1-1 cell line was obtained from M.-C.
Hung (The University of Texas M.D. Anderson Cancer Center). As previously described, each B104-1-1 cell is an NIH/3T3 cell derivative containing "~ 10 copies of the mutation-activated genomic neu oncogene (23) . B104-1-1 cells, NIH/3T3 cells, and their derivatives were maintained at 37~ in DME with 10% (vol/vol) bovine calf serum (BCS) (GIBCO BILL, Gaithersburg, MD). The packaging cell lines, GP + E-86 and PA317 (24, 25) and their derivatives were maintained in HXM complete medium (containing 15/~g/ml of hypoxanthine, 250/~g/ml of xanthine, and 25 ~g/ml of mycophenolic acid) and HAT complete medium (containing 1.36 mg/ml of hypoxanthine, 17.6 I~g/ml of aminopterin, and 378/~g/ml of thymidine). Each medium was supplemented with penicillin (5 U/ml) and streptomycin (5 U/ml). Plasmids, Transfections, and Infection. The PML retroviral construct pLPMLSN was constructed by inserting the full-length cDNA of PML (22) (26) . pLXSN or pLPMLSN were transfected into the ecotropic cell line GP+ E-86 or the amphotropic PA317 packaging cell lines by calcium phosphate coprecipitation (27, 28) . After 24 h of coprecipitation, the 1966 transfected packaging cells were split and grown in either HXM or HAT selective medium with 800/tg/ml of active G418. G418-resistant (G418 g) colonies were picked and expanded in selective medium and assayed for PML expression. The expression of transfected PML cDNA was determined by RNA slot blot analysis using the PML cDNA as described in our previous report (3) . Expression of the PML protein was determined by Western blotting as described below. The B104-1-1 cells, as target cells, were transduced with pLXSN or pLPMLSN by the supernatant gene transfer technique, as previously described (29) . In brief, B104-1-1 cells in exponential growth were plated with 106 cells in 100-mm culture dishes 1 d before recombinant virus infection. Each recipient culture dish was then fed with 10 ml of recombinant viral supernatant containing polybrene at a final concentration of 6/~g/ml. The recipient ceils were then infected with viral particles in the supernatant for 48 h. The viral supernatant was prepared by incubating fresh medium for I d with the growth-accelerated viral producer. The viral supernatant was then harvested and centrifuged at 3,000g for 5 min to remove cells and debris. The pLXSN-or pLPMLSN-containing virusinfected B104-1-1 cells were designated as B-LXSN and B-PMLSN, respectively. The transiently infected B-PMLSN cells were then split, selected, and expanded in DME complete medium containing 500 /~g/ml of G418. A G418 rt single-cell colony was selected and used directly for other experiments. The titers of recombinant retrovirus were determined using the NIH/3T3 cells and were expressed as G418 g NIH/3T3 CFU/ml (G418 rL CFU/ml) as previously described (30) .
Antibody, Gel Electrophoresis, and Immunoblotting. The antipeptide antibody against PML, PMI_,C7, was raised in rabbits as described in our previous report (22) . The neu oncogene product was detected by c-neu (Ab-3) mouse mAb (Oncogene .Science, Inc., Manhasset, NY). For expression analysis of PML or neu protein, cells were washed with cold PBS and scraped into 0.5 ml of RIPA buffer (10 mM Tris-HCL, pH 7.5, 120 mM NaC1, 1% NP-40, 1% deoxycholate, 0.1% SDS, 1 mM PMSF, 5/~g/ml leupeptin, 5/~g/ml aprotinin, 1 #g/ml pepstatin, and 50 mM sodium fluoride per 100-mm dish). After 15 min on ice, the lysed cells were spun at 5,000 g for 15 min at 4~ Protein samples were mixed 1:1 with 2x SDS sample buffer (containing 0.1 M Tris-HCl, pH 6.8, 0.2 M dithiothreitol, 4% SDS, 0.2% bromophenol blue, and 20% glycerol) and then heated to 100~ for 5 min before a 7.5% SDS-PAGE. After electrophoresis, proteins were transferred onto nitrocellulose filter (Schleicher & Schuell, Inc., Keene, NH) in a buffer containing 25 mM Tris, 192 mM glycine, and 20% methanol at 0.2 A for i h at 4~ Filters were then blocked by incubating overnight in Trisbuffered saline (TBS; 10 mM Tris, pH 8.0, 150 mM NaC1) containing 5% nonfat dried milk. The blots were then washed in TBS and incubated for 2 h with PML antibody or Ab-3. The primary antibody was removed and the blots were washed four times in TBS. To detect antibody reactions, the blots were incubated for 1.5 h with alkaline phosphatase-conjugated anti-rabbit or antimouse IgG (Bio-Rad Laboratories, Inc., Richmond, CA) diluted 1:2,000 in TBS, washed three times in TBS, and then placed in a buffer containing 100 mM Tris-HC1, pH 9.5, 100 mM NaC1, 5 mM MgCI2, 330/zg of Nitroblue tetrazolium/ml, and 150/~g of 5-bromo-4-chloro-3-indolyl phosphate/m for 10-20 min. Enzymatic color development was stopped by rinsing the filters in deionized water.
Immunofluorescence staining of the PML protein was performed by using the affinity-purified antipeptide antibody as previously described (22) .
[~H]Thymidine Incorporation. Transfectants of pLPMLSN in BI04-1-1 Cells. The G418 g pLPMLSN-containing recombinant virus producers were selected after transfecting the GP+ E-86 ecotropic packaging cell line with the recombinant retroviral construct pLPMLSN. Expression of the PML eDNA in these stable transfectants was confirmed by Western blotting. We found that two of six isolated packaging cell lines, designated GPE-PMLD and GPE-PMLF, expressed the 90-kD PML protein. For the negative control, we transfected the GP-E-86 and the PA317 packaging cell lines with pLXSN. Two clones of pLXSNcontaining recombinant virus producer were isolated. They were confirmed as clones by their ability to infect N I H / 3 T 3 cells and to produce G418 p" clones. In addition, Southern blot analysis of the genomic D N A isolated from these clones showed a 2.1-kb fragment of the BamHI/ApaLI-digested neomycin resistance gene (Neo p') sequence of pLXSN (our unpublished data). The virus-producing titers were determined by their ability to produce NeoP'-containing colonies after infection with N I H / 3 T 3 cells. The viral titers of the culture supernatants of GPE-PMLD and GPE-PMLF were determined to be 1.2-3.0 x 106 CFU/ml, and the titer of the pLXSN
Results
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Liu et al. recombinant virus producers (the control) was '~0.9-3.0 x 106 CFU/ml. Our antibody fails to detect the murine PML protein in the parental B104-1-1 or B-LXSN cells; however, as expected, after retroviral transduction, a 90-kD PML protein was detected ( Fig. 1) . 10 single colonies infected with recombinant GPE-PMLD or GPE-PMLF virus were isolated by selection in 500/~g/ml of G418. Three of the stable transfectants expressing the 90-kD PML protein by Western blotting (PML1, PML2, and PML3) were selected for further studies. Expression of the PML protein in PML1 and PML2 was demonstrated by immunofluorescence staining and Western blotting (Fig. 1, b and c) .
Effects of PML on the Morphology ofB104-1-1 Cells.
As shown in Fig. 2 , a-c, in comparison with its parental NIH/3T3 fibrobhst, B-104-1-1 ceUs showed the typical morphological characteristics of a transformed phenotype (32) (33) (34) . They showed more anchorage-independent and less contact limitation, and they were able to overlap and pile up even when some cells were separated from each other. The negative control experiment was conducted by mock infection of B104-1-1 cells with pLXSN-containing virus. These cells demonstrated G418 resistance but showed no discernable change in their morphology (our unpublished data). On the other hand, PML1 and other PML-stable transfectants (PML2 and PML3) showed a more differentiated morphology. These cells become more anchorage dependent and more contact limited. The cell volume became larger, and the cytophsm/nucleus ratio significantly increased. The morphology of the PML-expressing B104-1-1 cells appears to be similar to that of the wild-type NIH/3T3 cells. This result indicates that the expression of PML in B104-1-1 cells suppressed the transformation phenotype. Under serum-deprived conditions, morphology of NIH/3T3, B104-1-1, and the PML1 cells appeared significantly different from each other (Fig. 2, d-j) . A significant number of cytoplasmic vacuoles were found in the PML1 cells.
Effects of PML Expression on Clonogenicity in Sofi-Agar Assay and Tumorigenicity in Nude Mice. According to the results
of these studies, PML is able to suppress the transformed phenotype of B104-1-1 cells. To investigate whether PML also suppresses the donogenicity of these cells, we first tested the effects of constitutive PML expression on the anchorageindependent growth of 8104-1-1 calls on soft agar. As shown in Fig. 3 , the negative (mock-infected) control, that is, B-LXSN-infected cells, showed no suppression of colony formation in soft agar assay. However, the number of colonies formed in the B-PMLSN-infected B104-1-1 cells was sig-
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PML Suppresses neu-transformed NIH/3T3 Cells nificantly suppressed (up to 68%). Stable transfectants obtained from single colonies, PML1, PML2, and PML3, were able to suppress 89-94% of its C F U on soft agar. The effects of PML on tumorigenicity of the B104-1-1 cells were assayed in athymic nude mice. As shown in Table 1 , all nude mice injected with 105 B104-1-1 cells formed tumors as early as day 8. Similar results were observed in the group of mice injected with mock-infected B104-1-1 cells. No difference in the time to tumor appearance, average tumor size, or average tumor weight were found between the two groups of mice. However, the appearance of tumor was delayed until day 10 in nude mice that were injected with PML3 cells and until day 14 in those that were injected with PML2 cells; Athymic nude mice of the same age were subcutaneously injected with 10 s cells from each clone into the flanks. Tumor volume was determined with a tumorimeter. Tumor-bearing mice were killed on day 17, after which the tumors were removed and their apparent weights were recorded. " An average of tumor volume and weight from four mice. Days after injection.
been used as a parameter to measure growth-affecting cells. B104-1-1, a neu-transformed NIH/3T3 fibroblast line, has been demonstrated to have an elevated growth rate (34) . We thus determined the effect of PML expression on growth of the B104-1-1 cells by monitoring [3H]thymidine incorporation. The results presented in Fig. 4 indicate that no significant changes in thymidine incorporation were found in mockinfected cells. However, a significant reduction in thymidine incorporation was found in cells that were transfected with pLPMLSN and that expressed the PML protein (PML1 and PML2). Therefore, PML expression in the B104-1-1 cells could reverse, to a variable degree, the rate of DNA synthesis when ceils were cultured under normal conditions. This observation of growth suppression by PML was further demonstrated by determining the growth curves of different cell types in the presence of various concentrations of BCS (10%, 0.5%).
The results presented in Fig. 5 indicate that all cells expressing the PML protein showed a slower growth rate. The difference in growth rate between the mock-infected controls and the PML-expressing cells was more dramatic when the cells were cultured under low serum conditions. However, the effects of PML on the phase distribution of the cell cycle ap-
Days a peared to be subtle and were insignificant either at normal or serum-deprived conditions ( Table 2) .
Effects of PML on the Expression of neu Oncogene. To in-
vestigate the mechanism of the PML suppression effect on B104-1-1 cells, we analyzed whether expression of PML protein in these cells affected the expression of neu. The neu gene encodes a 185-kD transmembrane protein of the tyrosine kinase receptor family (35) (36) (37) . As shown in Fig. 6 a, B104-1-1 cells expressed high levels of the 185-kD NEU protein in both its phosphorylated (upper band) and unphosphoryhted (lower band) forms. Expression of NEU in the GPE-PMLD-and GPE-PMLF-infected cells did not show any significant difference when compared with that of B104-1-1 and the mockinfected control. However, its expression was significantly suppressed in the stable PML transfectants, although a moderate level of NEU was still detectable in these cells (Fig.  6 b) . Immunofluorescence staining of these cells indicated that almost 100% of the cells were PML + . This observation demonstrated that constitutive expression of PML in the neutransformed NIH/3T3 cells significantly affects the expression of the NEU protein in vivo. Therefore, we conclude from these studies that PML did not significantly affect the expression of NEU in the transient assay, but did produce a dramatic reduction in NEU expression in the stable transfectants. Since there are 10 copies of activated neu oncogene transfected in the B104-1-1 cells, and high levels of the NEU protein is constitutively expressed, the moderate expression of NEU protein in the two stable transfectants suggested that constitutive expression of PML in these ceUs did not completely suppress the expression of activated NEU. Our results also suggest that growth suppression of the B104-1-1 cells by PML is a result of suppressing neu expression and the signals arising from the NEU protein. 
Discussion
The characteristic morphology of the activated neutransformed NIH/3T3 cell line B104-1-1 makes it a good model for analyzing the functions of gene products that can affect the expression or the function of the activated neu oncogene. The B104-1-1 cell line in culture exhibited less anchorage dependence and less contact limitation by piling up and overlapping, especially during confluence. Our study demonstrated that the transformed phenotype could be reversed by infection with a retrovirally transduced P M L gene. We have shown that PML is able to suppress anchorage-independent growth ofB104-1-1 cdls on soft agar. Furthermore, PML also suppressed activated-neu-induced transformation, which was demonstrated most stringently by the suppression of tumor formation in nude mice. These results indicated that PML can reverse neu-induced transformation. Since PML is a putative zinc finger transcription factor, this result implies that PML affects the activated neu oncogene either by inhibiting neu expression or by blocking the signals transduced by the NEU protein. Our results as shown in Fig. 6 suggest that constitutive expression of PML in B104-1-1 ceils suppresses both the expression and biologic function of the neu gene. Suppression of NEU function in a neu-transformed cell line resulted in cell cycle arrest at the G2/M phase (38, 39) . However, PML-suppressed transformation of B104-1-1 cells did not significantly affect the cell cycle phases (Table 2 ), indicating that the effect of the molecular mechanism of PML suppression of neu is different from the effect of using specific monoclonal antibody against the NEU receptor (38, 39). In addition, morphology of PML1 is different from NIH/3T3 under serum-deprived conditions (Fig. 2) .
The activated neu oncogene transfected in the B104-1-1 cell contains a single amino acid substitution in the transmembrane domain, and it has higher tyrosine kinase activity than its normal counterpart (40--43) . By Western blotting, we found that PML had only subtle effects on neu expression in the transient expression assay. However, the subtle change in neu expression cannot explain the significant reversal of the transformed phenotype and growth suppression that occurred in the PML-expressing B104-1-1 line. These results suggest that PML can reverse the neu-transformed phenotype of B104-1-1 cells and that this effect does not result from the suppression of neu expression, but mostly from the inhibition of signal transduction induced by activated neu.
Although the effects of tumorigenicity suppression by PML can be associated with that of growth retardation (31, 44, 45) , the growth-suppressing effects of PML were demonstrated by decreased thymidine incorporation in PML-expressing B104-1-1 cells (B-PMLSN, PML1, PML2, and PML3). This was also reflected by the concordant suppression of cell growth in PML-expressing B104-1-1 lines shown in growth curves. The growth suppression effect of PML was more noticeable under conditions of serum deprivation. From our analysis of cell cycle distribution, it was clear that serum deprivation did arrest more fibroblasts in the G0/G1 phase, but that no significant difference resulted from the expression of PML. Thus, it is possible that the growth difference resulting from PML expression, especially in conditions of serum deprivation, came from a survival disadvantage, but not from cell cycle redistribution.
Our findings demonstrate that PML functions as a growth suppressor gene and, although it has yet to be demonstrated prospectively, the disruption of PML suppressor function after the t(15;17) will likely be an important contributor to the development of leukemic transformation.
In our previous study, we convincingly demonstrated that PML is a growth suppressor based on the following findings: (a) PML suppressed the anchorage-independent growth of APL-derived NB4 cells on soft agar and tumorigenidtr in nude mice; (b) PML suppressed the oncogenic transformation of rat embryo fibroblast by cooperative oncogenes; and (c) PML suppressed transformation of NIH/3T3 cells by activated neu oncogene (22) . We also showed by a cotransfection experiment that PML-RARo~ can suppress the transformation suppressor function of PML, possibly by a dominant negative-inhibitory effect. Our recent results demonstrated that PML is a phosphoprotein, and that at least one of the sites is phosphorylated by a tyrosine kinase. Our recent study also showed that PML is associated with the nuclear matrix (46) . In addition to these results, we also found that PML is a promoter-specific transcription suppressor (22) . Therefore, from these studies, we conclude that PML, the gene disrupted by the translocation breakpoint in APL, has many similar properties to tumor suppressors, for example, retinoblastoma gene product (Rb).
The mechanism of neu transformation may be coupled to phosphatidylinositol turnover through tyrosine phosphorylation of phospholipase C (PLC) (46, 47) . It was also found in activated neu-transformed cells that PLC 3, is constitutively phosphorylated on the tyrosine residues and forms a kinasedependent complex with the mutation-activated neu receptor
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